Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eyepoint Pharmaceuticals Inc (EYPT)

Eyepoint Pharmaceuticals Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,384,199
  • Shares Outstanding, K 82,787
  • Annual Sales, $ 43,270 K
  • Annual Income, $ -130,870 K
  • EBIT $ -218 M
  • EBITDA $ -223 M
  • 60-Month Beta 1.67
  • Price/Sales 27.78
  • Price/Cash Flow N/A
  • Price/Book 6.00

Options Overview Details

View History
  • Implied Volatility 65.49% (-28.64%)
  • Historical Volatility 81.38%
  • IV Percentile 3%
  • IV Rank 8.65%
  • IV High 195.01% on 04/08/25
  • IV Low 53.23% on 07/30/25
  • Expected Move (DTE 14) 0.94 (5.27%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 404
  • Volume Avg (30-Day) 189
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 13,247
  • Open Int (30-Day) 14,636
  • Expected Range 16.81 to 18.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.74
  • Number of Estimates 3
  • High Estimate -0.65
  • Low Estimate -0.85
  • Prior Year -0.64
  • Growth Rate Est. (year over year) -15.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.28 +72.57%
on 11/07/25
17.82 -0.45%
on 12/05/25
+6.72 (+60.98%)
since 11/05/25
3-Month
9.65 +83.83%
on 11/05/25
17.82 -0.45%
on 12/05/25
+3.73 (+26.62%)
since 09/05/25
52-Week
3.91 +353.71%
on 04/09/25
17.82 -0.45%
on 12/05/25
+9.58 (+117.40%)
since 12/05/24

Most Recent Stories

More News
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYUâ„¢ in Wet Age-Related Macular Degeneration

– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU –...

EYPT : 17.74 (+6.10%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...

EYPT : 17.74 (+6.10%)
EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EYPT : 17.74 (+6.10%)
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU ™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME...

EYPT : 17.74 (+6.10%)
EyePoint Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

EYPT : 17.74 (+6.10%)
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

EYPT : 17.74 (+6.10%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...

EYPT : 17.74 (+6.10%)
EyePoint Pharmaceuticals Launches Phase 3 DURAVYU Program

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. EyePoint...

EYPT : 17.74 (+6.10%)
EyePoint Announces Pricing of Public Offering

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

EYPT : 17.74 (+6.10%)
EyePoint Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

EYPT : 17.74 (+6.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known...

See More

Key Turning Points

3rd Resistance Point 19.41
2nd Resistance Point 18.61
1st Resistance Point 18.18
Last Price 17.74
1st Support Level 16.95
2nd Support Level 16.15
3rd Support Level 15.72

See More

52-Week High 17.82
Last Price 17.74
Fibonacci 61.8% 12.51
Fibonacci 50% 10.86
Fibonacci 38.2% 9.22
52-Week Low 3.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar